These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 3815721)

  • 1. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
    Roed H; Vindelov LL; Christensen IJ; Spang-Thomsen M; Hansen HH
    Cancer Chemother Pharmacol; 1987; 19(1):16-20. PubMed ID: 3815721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
    Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Moritaka T; Tabata M; Segawa Y; Shibayama T; Gemba K; Matsumura T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):473-7. PubMed ID: 8383949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.
    Nissen NI; Dombernowsky P; Hansen HH; Pedersen AG
    Recent Results Cancer Res; 1980; 74():98-106. PubMed ID: 7003663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
    Colombo T; Broggini M; Vaghi M; Amato G; Erba E; D'Incalci M
    Eur J Cancer Clin Oncol; 1986 Feb; 22(2):173-9. PubMed ID: 3699080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation.
    Jensen PB; Roed H; Skovsgaard T; Friche E; Vindeløv L; Hansen HH; Spang-Thomsen M
    Cancer Chemother Pharmacol; 1990; 27(3):194-8. PubMed ID: 2265455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1987; 9():67-70. PubMed ID: 3079416
    [No Abstract]   [Full Text] [Related]  

  • 8. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.
    Dorr RT; Alberts DS
    Invest New Drugs; 1983; 1(2):151-9. PubMed ID: 6678864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Podophyllotoxin derivatives VP-16 and VM-26.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1988; 10():57-63. PubMed ID: 3079398
    [No Abstract]   [Full Text] [Related]  

  • 12. [Etoposide effect on cell cycle kinetics of a human lung cancer cell line].
    Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Inoue S; Kawakami Y; Mizuno S
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1237-43. PubMed ID: 6732252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures.
    Chapuis JC; Keng PC; Siemann DW
    Anticancer Drugs; 1992 Jun; 3(3):245-52. PubMed ID: 1525405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of an etoposide-resistant human epithelial tumour cell line in vitro: characterization of patterns of cross-resistance and drug sensitivities.
    Hill BT; Bellamy AS
    Int J Cancer; 1984 May; 33(5):599-608. PubMed ID: 6539305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VM 26 and VP 16-213: a comparative analysis.
    Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
    Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
    Woynarowski JM; Sigmund RD; Beerman TA
    Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.
    Vietti TJ; Valeriote FA; Kalish R; Coulter D
    Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activity of galactopyranoside derivatives of 4'-demethylepipodophyllotoxin showing VP-16 (etoposide)-like activity.
    Pamidi CC; Derry WB; Gupta RS
    Anticancer Drug Des; 1991 Nov; 6(5):481-93. PubMed ID: 1764166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.
    Yalowich JC; Fry DW; Goldman ID
    Cancer Res; 1982 Sep; 42(9):3648-53. PubMed ID: 6179605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.